English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu
“Laboratory testing is not as simple as running a sample through a machine. The results must be interpreted and developed into a clinical report that laboratories either need to design and build, or they can partner with providers like Coriell Life Sciences. To speed our national response to stemming the spread of the COVID-19 virus, we feel we can contribute by creating a ready-made path for laboratories ramping up access to this testing.” said Scott Megill, President and CEO of Coriell Life Sciences.
Coriell Life Sciences is uniquely positioned to respond to respiratory illnesses such as Coronavirus (COVID-19). CLS’ Infectious Disease Reporting interprets semi-quantitative laboratory assays of pathogenic microorganisms. Coriell Life Sciences recognizes the need to implement testing and reporting solutions immediately. With so many citizens at risk for infection and the national focus on preventing the spread of the disease, we aim to make our process as simple and efficient as possible while healthcare organizations continue to pursue Emergency Use Authorization (EUA).
For any existing or new laboratory partner to initiate the process, those interested can contact Coriell Life Sciences by completing the request form located here, calling 888-415-7834, or emailing [email protected].
About Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine. We are a trusted bioinformatics company that bridges the gap between genetic knowledge and clinical application to drive cost-effective healthcare solutions for laboratories, payers, systems, providers, and patients. Coriell Life Sciences sets the gold standard in genetic interpretation and reporting and offers the most comprehensive medication risk management program on the market. Visit coriell.com, email [email protected], or follow @CoriellLife.
Original post https://alertarticles.info
